Research & Development
R & D

Biotechnology

생명이미지

Competitive advantage based on superior technology and R&D capabilities in the red bio market.

Based on the superior bio technology and R&D capability, we have developed various new original medicines like first pediatric growth hormone and nation's first diabetes medicine, and we are expanding our competitive advantages in overseas by business cooperation with global pharmaceutical company.

Business Status

  • 01

    LDPE (including EVA)

    No.1 share in the domestic market
  • 02

    Specialized/Differentiated Products

    69% of whole sale
  • 03

    One of the three
    biggest compound makers

  • 04

    Korea's largest LDPE and LLDPE
    production facilities

Whois Chemical is positioned as a leading company of Asian synthetic resin market by reorganizing portfolio into high value products which accord with customer's need not the existing universal products. As a result, HDPE/FMF PP have been selected as world-class products so that our superior product competitiveness was recognized throughout the world.
Whois chemical will lead the high value Asian synthetic resin market by boosting production through building additional NCC plants, widening market share of Terpolymer PP, building additional ADL (Advanced Double Loop) plants for increasing output of high value PE products

Use of products

  • 합성의약

    Synthetic drugs

  • 에스테틱

    Esthetic

  • 진단의약

    Diagnostic drugs